Jakavi

Jakavi

ruxolitinib

Manufacturer:

Novartis Healthcare

Distributor:

Novartis Healthcare
Concise Prescribing Info
Contents
Ruxolitinib phosphate
Indications/Uses
Treatment of patients w/ myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis; patients w/ polycythemia vera who are resistant to or intolerant of hydroxyurea; patients w/ graft-versus-host disease ≥12 yr who have inadequate response to corticosteroids or other systemic therapies.
Dosage/Direction for Use
Myelofibrosis Platelet count >200,000/mm3 Recommended starting dose: 20 mg bid; platelet count between 100,000/mm3 & 200,000/mm3 15 mg bid; platelet count between 50,000/mm3 & 100,000/mm3 Max: 5 mg bid. Dose reductions should be considered if the platelet counts decrease <100,000/mm3. Max dose: 25 mg bid. Polycythemia vera & graft-versus-host disease Initially 10 mg bid. For polycythemia vera, dose reduction should be considered if Hb decreases 10-12 g/dL. Max dose: 25 mg bid. Severe renal impairment Myelofibrosis Starting dose based on platelet count should be reduced by approx 50%. Polycythemia vera 5 mg bid. Patients w/ ESRD on hemodialysis Myelofibrosis Initially 15 or 20 mg based on platelet counts w/ subsequent single doses only after each dialysis session. Polycythemia vera 10 mg or 2 doses of 5 mg given 12 hr apart administered post-dialysis & only on the day of haemodialysis.
Administration
May be taken with or without food.
Contraindications
Special Precautions
Monitor CBC. Serious bacterial, mycobacterial, fungal, viral & other opportunistic infection. Herpes zoster. Progressive multifocal leukoencephalopathy (PML). Non-melanoma skin cancers (NMSCs), including basal cell, squamous cell & Merkel cell carcinoma. Increases in lipid parameters including total cholesterol, HDL cholesterol, LDL cholesterol & triglycerides. Avoid abrupt discontinuation. Renal & hepatic impairment. Pregnancy & lactation. Childn. Elderly.
Adverse Reactions
UTI, herpes zoster, pneumonia; bruising, thrombocytopenia, neutropenia; hypercholesterolemia, hypertriglyceridemia, wt gain; dizziness, headache; constipation; raised ALT & AST; HTN.
Drug Interactions
Increased AUC w/ ketoconazole, erythromycin, fluconazole.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01EJ01 - ruxolitinib ; Belongs to the class of Janus-associated kinase (JAK) inhibitors. Used in the treatment of cancer.
Presentation/Packing
Form
Jakavi tab 15 mg
Packing/Price
14's
Form
Jakavi tab 20 mg
Packing/Price
14's
Form
Jakavi tab 5 mg
Packing/Price
14's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in